haloperidol has been researched along with selegiline in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (21.88) | 18.7374 |
| 1990's | 4 (12.50) | 18.2507 |
| 2000's | 15 (46.88) | 29.6817 |
| 2010's | 6 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cohen, G | 1 |
| Cohen, G; Spina, MB | 1 |
| Defazio, G; Ferrari, E; Lamberti, P; Lepore, V; Livrea, P | 1 |
| Kaakkola, S; Männistö, PT; Nuutila, J | 1 |
| Anderson, B; Severson, JA | 1 |
| Bizière, K; Kan, JP; Roncucci, R; Wermuth, CG; Worms, P | 1 |
| Knoll, B; Knoll, J; Timar, J | 1 |
| Flórez, J; Mediavilla, A; Pazos, A | 1 |
| Cadet, JL; Gewirtz, GR; Gorman, JM; Sarti, P; Sharif, Z | 1 |
| Baudewig, J; Bruns, D; Paulus, W; Tergau, F; Ziemann, U | 1 |
| Wu, WR; Zhu, XZ | 1 |
| Alper, RH; Gilliland, SL; Levant, B | 1 |
| Marsh, C; Preskorn, SH; Shad, MU | 1 |
| Arya, P; Butler, R; Warner, J | 1 |
| Preskorn, SH | 1 |
| Gomita, Y; Kawasaki, H; Kimoto, S; Kitagawa, K; Kitamura, Y; Sagara, H; Sendo, T; Shibata, K | 1 |
| Ali, J; Baboota, S; Dang, S; Kumar, S; Nigam, K | 1 |
2 review(s) available for haloperidol and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
1 trial(s) available for haloperidol and selegiline
| Article | Year |
|---|---|
Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs.
Topics: Administration, Oral; Adult; Analysis of Variance; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Electromyography; Evoked Potentials, Motor; Female; Haloperidol; Humans; Levodopa; Magnetics; Male; Motor Cortex; Physical Stimulation; Reference Values; Selegiline; Sulpiride | 1997 |
29 other study(ies) available for haloperidol and selegiline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Monoamine oxidase and oxidative stress at dopaminergic synapses.
Topics: Animals; Clorgyline; Corpus Striatum; Dopamine; Glutathione; Glutathione Reductase; Haloperidol; In Vitro Techniques; Levodopa; Male; Mice; Monoamine Oxidase; Oxidation-Reduction; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Stress, Physiological; Substantia Nigra; Synapses; Synaptosomes | 1990 |
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
Topics: Animals; Corpus Striatum; Dopamine; Enzyme Inhibitors; Glutathione; Glutathione Disulfide; Haloperidol; Male; Mice; Monoamine Oxidase; Oxidation-Reduction; Phenethylamines; Selegiline | 1989 |
Facial dystonia: clinical features, prognosis and pharmacology in 31 patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Botulinum Toxins; Drug Combinations; Female; Haloperidol; Humans; Levodopa; Male; Meige Syndrome; Middle Aged; Phenethylamines; Prognosis; Selegiline | 1989 |
Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.
Topics: Animals; Behavior, Animal; Catalepsy; Catechol O-Methyltransferase Inhibitors; Central Nervous System; Haloperidol; Levodopa; Male; Motor Activity; Phenethylamines; Propiophenones; Rats; Selegiline; Specific Pathogen-Free Organisms | 1987 |
Chronic antidepressant treatment and mouse brain 3H-imipramine binding.
Topics: Animals; Antidepressive Agents; Binding Sites; Cerebral Cortex; Desipramine; Haloperidol; Imipramine; Male; Mice; Mice, Inbred C57BL; Receptors, Adrenergic, beta; Receptors, Dopamine; Receptors, Dopamine D2; Selegiline | 1986 |
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Body Temperature; Catalepsy; Clorgyline; Drug Interactions; Female; Haloperidol; Imipramine; Levodopa; Male; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Nomifensine; Oxotremorine; Pargyline; Piperidines; Pyridazines; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Stereotyped Behavior | 1987 |
Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.
Topics: Animals; Apomorphine; Clorgyline; Dextroamphetamine; Drug Interactions; Female; Haloperidol; Imipramine; Male; Phenethylamines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Selegiline; Stereotyped Behavior | 1986 |
Cardiovascular effects of intracerebroventricular injection of dopamine after selective MAO inhibition in rats.
Topics: Animals; Blood Pressure; Clorgyline; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Heart Rate; Injections, Intravenous; Male; Monoamine Oxidase Inhibitors; Phentolamine; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Dopamine; Selegiline | 1982 |
Selegiline for neuroleptic-induced parkinsonism.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Schizophrenia; Selegiline | 1993 |
The amphetamine-like reinforcing effect and mechanism of L-deprenyl on conditioned place preference in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Conditioning, Operant; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Reinforcement, Psychology; Selegiline | 1999 |
Pharmacology of quinpirole-stimulated [35S]GTPgammaS binding: discrepancy with receptor binding profile.
Topics: Animals; Benzazepines; Binding, Competitive; Clorgyline; Clozapine; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Male; Membranes; Monoamine Oxidase Inhibitors; Quinpirole; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Selegiline; Spiperone; Sulfur Radioisotopes; Thiazoles | 2000 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl | 2001 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; Dementia; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxetine; Haloperidol; Hospitalization; Humans; Hypnotics and Sedatives; Lorazepam; Parkinson Disease; Psychomotor Agitation; Selegiline; Trihexyphenidyl | 2008 |
Selegilin exerts antidepressant-like effects during the forced swim test in adrenocorticotropic hormone-treated rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Benzazepines; Cosyntropin; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Models, Animal; Monoamine Oxidase Inhibitors; Motor Activity; Naphthalenes; Pyrrolidines; Rats; Rats, Wistar; Receptors, Dopamine D3; Selegiline; Swimming; Time Factors | 2008 |
Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Compounding; Haloperidol; Male; Nanoparticles; Oxidative Stress; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Up-Regulation | 2018 |